Ramucirumab: A vascular endothelial growth factor receptor-2 inhibitor with activity in several malignancies

American Journal of Health-System Pharmacy

Volumn 73, Issue 13, 2016, Pages 957-968

  Grabowski, Jennifer ^a   Glode, Ashley ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PACLITAXEL; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; KDR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ARTERIAL THROMBOEMBOLISM; BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG COST; DRUG MONITORING; DRUG SAFETY; DYSPHAGIA; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FISTULA; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYPERTENSION; INFUSION RELATED REACTION; KIDNEY CARCINOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUNG CANCER; METASTATIC COLORECTAL CANCER; MONOTHERAPY; NAUSEA; NEPHROTIC SYNDROME; NEUROPATHY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; THYROID DISEASE; TRANSITIONAL CELL CARCINOMA; VENOUS THROMBOEMBOLISM; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; NEOPLASMS; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84976345090     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp150188     Document Type: Review

References (24)

1. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005; 23:1011-27.
2. Spratlin JL, Cohen RB, Eadens M et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010; 28:780-7.
3. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008; 358:2039-49.
4. Mittal K, Ebos J, Rini B. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. Semin Oncol. 2014; 41:235-51.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-74.
6. Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014; 17:471-94.
7. Cyramza (ramucirumab) package insert. Indianapolis, IN: Eli Lilly and Company; 2014 Dec.
8. Aprile G, Rijavec E, Fontanella C et al. Ramucirumab: preclinical research and clinical development. Onco Targets Ther. 2014; 7:1997-2006.
9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer, v.2.2015. www.nccn.org (accessed 2015 Mar 17).
10. National Cancer Institute. Surveillance Epidemiology and End Results. www.seer.cancer.gov/statfacts (accessed 2015 Mar 17).
11. American Cancer Society. Cancer facts and figures 2015. www.cancer. org/acs/groups/content/@editorial/documents/document/acspc-044552. pdf (accessed 2015 Mar 18).
12. Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014; 383:31-9.
13. Wilke H, Muro K, Van Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15:1224-35.
14. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer, v.5.2015. www.nccn. org (accessed 2015 Mar 17).
15. Garon EB, Cao D, Alexandris E et al. A randomized, double-blind, phase III study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design. Clin Lung Cancer. 2012; 13:505-9.
16. Garon EB, Ciuleanu TE, Arrieta O et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014; 384:665-73.
17. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer, v3.2015. www.nccn.org (accessed 2015 Jun 17).
18. Taberno J, Cohn AL, Obermannova R et al. RAISE: a randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). J Clin Oncol. 2015; 33 (suppl 3): abstract 512.
19. Zhu AX, Ryoo BY, Yen CJ et al. A multicenter, randomized, double-blind, phase 3 study of ramucirumab (IMC-1121B) drug product and best supportive care (BSC) versus placebo and BSC as second-line treatment in patients with hepatocellular carcinoma following first-line therapy with sorafenib (REACH). Paper presented at the 2014 European Society of Medical Oncology Conference. Madrid, Spain; 2014 Sep.
20. Ramucirumab: drug information. In: Lexicomp Online [online database]. Hudson, OH: Lexi-Comp (accessed 2015 Jul 15).
21. Zhu AX, Ryoo BY, Yen CJ et al. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): analysis of patients with elevated a-fetoprotein (AFP) from the randomized phase III reach study. Paper presented at the 2015 Gastrointestinal Cancers Symposium. San Francisco, CA; 2015 Jan.
22. Garcia JA, Hudes GR, Choueiri TK et al. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer. 2014; 120:1647-55.
23. Doebele R, Spigel D, Tehfe M et al. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015; 121:883-92.
24. Petrylak DP, Tagawa ST, Kohli M et al. Interim results of a randomized phase II study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma. Paper presented at the 2015 Genitourinary Cancers Symposium. Orlando, FL; 2015 Feb.